Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

302.00 +3.05 (+1.02%)
Streaming Delayed Price Updated: 9:34 AM EDT, Mar 21, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel. 
Via MarketBeat
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 15 Years
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 15 years by 11.12% on an annualized basis producing an average annual return of 17.93%. Currently, Vertex Pharmaceuticals... 
Via Benzinga
3 Top Healthcare Stocks Defying the Bear Market
These healthcare companies haven't been slowed by macroeconomic conditions. 
Via The Motley Fool
Vertex to Participate in Upcoming Investor Conferences
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Here's a No-Brainer Stock to Buy Now That's Trouncing the Market
There are five great reasons this stock should continue to soar. 
Via The Motley Fool
Why Shares of Vertex Pharmaceuticals Jumped 9.03% on Friday
A strong earnings report after the close on Thursday pushed the stock higher all day Friday. 
Via The Motley Fool
Vertex Pharmaceuticals (VRTX) Q3 2022 Earnings Call Transcript
VRTX earnings call for the period ending September 30, 2022. 
Via The Motley Fool
3 Healthcare Stocks That Could Go Parabolic
These beaten-down stocks are ready for a rebound. 
Via The Motley Fool
Got $1,000? 2 Smart Stocks to Consider Buying Right Now
Don't overlook these major healthcare names on your next stock-buying spree. 
Via The Motley Fool
Got $1,000? 2 No-Brainer Stocks to Buy and Hold for at Least the Next Decade
Don't let these stocks pass you by. 
Via The Motley Fool
Don't Overlook This $104 Billion Item Buried In Amazon's Latest Report
The number is big -- but it might not be growing like it once was. 
Via The Motley Fool
4 Growth Stocks to Buy and Hold Forever
If you're hunting for top growth stocks on sale, you've come to the right place. 
Via The Motley Fool
2 Biotech Stocks That Could Make You Richer
Both drugmakers are pretty close to their 52-week highs, but that shouldn't stop investors. 
Via The Motley Fool
Vertex Pharmaceuticals Jumps After Quarterly Beat, Raises 2022 Outlook
Shares tumbled 7.5% during the regular session, ahead of the quarterly beat. 
Via Investor's Business Daily
Vertex Announces Partnership with Basketball Hall-of-Famer Alonzo Mourning to Raise Awareness of APOL1-Mediated Kidney Disease (AMKD)
From Vertex Pharmaceuticals Incorporated
Via Business Wire
3 Top Healthcare Stocks to Buy for November
Catalysts lie ahead for these promising stocks. 
Via The Motley Fool
Vertex to Present New Data on its Portfolio of Cystic Fibrosis Medicines at the 2022 North American Cystic Fibrosis Conference
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Bear Market Investing: Should You Buy Today's Top Performers?
Some stocks are defying the bear market. 
Via The Motley Fool
3 Nasdaq 100 Stocks to Buy Hand Over Fist in November
The innovation-packed Nasdaq 100 has three screaming bargains that are ripe for the picking. 
Via The Motley Fool
Is Vertex Pharmaceuticals About to Become a Dividend Stock?
The big biotech has a cash stockpile of nearly $10 billion. Here's how Vertex plans to use the money. 
Via The Motley Fool
Can Biotech Stocks Continue Rallying In This Bear Market?
Via Talk Markets
The Best Stocks to Invest $20,000 in Right Now
A long-term investment in any of these powerhouse stocks could reap generous returns for many years to come. 
Via The Motley Fool
5 Top Stocks for November
A dynamic blend of growth, value, and dividend stocks worth considering now. 
Via The Motley Fool
This Bear Market Could Be the Best Investing Opportunity in More Than a Decade
It could be time to party like it's 2009. 
Via The Motley Fool
Stock Market Rally Resilient As Apple Bucks Megacap Meltdown: Weekly Review
The Dow and S&P 500 moved above a key level while the Nasdaq rose. 
Via Investor's Business Daily
Cramer Says Stay With This Stock As It Is 'Really, Really Well-Run Company'
On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended staying with Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), and added that it’s a "really, really well-run company." 
Via Benzinga
Vertex Reports Third Quarter 2022 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Pharmaceuticals Unusual Options Activity For October 27
A whale with a lot of money to spend has taken a noticeably bearish stance on Vertex Pharmaceuticals. Looking at options history for Vertex Pharmaceuticals (NASDAQ:VRTX) we detected 13 strange trades. 
Via Benzinga
US Stocks On Track For Mixed Start As Nasdaq Futures Sag Yet Again Amid Big Tech Woes; Traders Look Ahead To Q3 GDP Data, Apple, Amazon Earnings
Trading in the U.S. index futures points to a mixed opening by Wall Street stocks on Thursday, as tech earnings continue to disappoint. 
Via Benzinga
Earnings Scheduled For October 27, 2022
Companies Reporting Before The Bell • Janus Henderson Gr (NYSE:JHG) is expected to report quarterly earnings at $0.48 per share on revenue of $494.27 million. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.